Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2025-11-27 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Medincell management will be participating in upcoming healthcare investor conferences. It provides details on the dates, times, and links for these presentations. It does not contain the actual presentation materials, nor is it a financial report, audit, or regulatory filing of a specific event result. It falls under the category of general regulatory announcements/corporate communications regarding investor relations activities.
2025-11-27 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing the participation of Medincell's management in upcoming healthcare conferences (Evercore and Piper Sandler). It provides details on the dates, times, and webcasts for these events. It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into more specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-27 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Medincell announcing a new $3 million grant from the Gates Foundation to advance their malaria program. It details the nature of the program, the funding, and provides corporate background information. It does not fit into specific categories like financial reports, voting results, or director dealings. As it is a general corporate announcement regarding business operations and funding, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-11-24 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Medincell announcing a new grant from the Gates Foundation for their mdc-STM malaria program. It details the nature of the grant, the scientific background of the program, and quotes from company leadership. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it provides substantive news content. It falls under the general category of regulatory/corporate announcements.
2025-11-24 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Medincell's management will participate in a fireside chat at the Jefferies London Healthcare Conference 2025. It includes details about the event, company overview, contact information, and forward-looking statements. There is no financial data, no detailed report, no voting results, no regulatory filing, no audit information, and no mention of any report being attached or published. The document is a corporate announcement about a management presentation at a conference, which aligns with an Investor Presentation announcement. However, since it is a press release about participation in a conference event rather than the presentation itself, and it does not contain the presentation content, it is best classified as a Regulatory Filing (RNS) as a general corporate announcement. The document length is moderate (5857 characters), but it does not contain substantive financial or report data to classify as a financial report or presentation.
2025-11-13 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 13, 2025, announcing that Medincell's management team will participate in a strategic discussion at the Jefferies Healthcare conference. It includes details about the event, company background, contact information, and disclaimers about forward-looking statements. There is no financial data, no detailed report content, no voting results, no regulatory filings, or any other specific report type content. The document is informational and promotional in nature, typical of a press release or announcement. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. Given the nature and content, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement or press release that does not fit other categories.
2025-11-13 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.